Feeds:
Posts
Comments

Archive for the ‘Roche’ Category

*****

TODAY’S NEWS:

We’re in the pre-ASCO oncology news build-up phase. Here’s a brief preview. And even more here.

Does HGH really help athletes? Interesting article – the last paragraph is the kicker.

Whistleblowers (J&J) get a payday. And, allegations about illegal sales practices by Roche with Tamiflu.

RECOMMENDED

eLearning. We know that space inside and out, and we have great partners to recommend. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Karl Schmieder of MessagingLab interviews me about Impactiviti. Plus – the timing is never really “right,” is it? 29 and Counting.

JUST FOR FUN

If this doesn’t make you want to visit South America some day, nothing will!

AND, a pharma spoof – So, What’s your Problem with Gram-Negative Bacteria?

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS

It appears that the 3-way bidding war for Ratiopharm is going to be won by Teva. So, who will Pfizer go after next?

Abraxis jumps after successful lung cancer comparative trial – The Abraxis product, Abraxane, combines paclitaxel with a human protein to administer it in higher doses, according to company data. During the trial, in the third of three phases generally required for regulatory approval of a medicine, Abraxane showed a more successful response rate in treating non- small cell lung cancer than paclitaxelmore

Roche bullish on some pipeline drugs for cancer and cholesterol – The chief executive of Roche Holding AG said on Wednesday the Swiss drugmaker’s experimental drugs to treat melanoma and raise “good” HDL cholesterol could transform treatment of cancer and heart disease. In an interview, Roche Chief Executive Officer Severin Schwan said its drug designed to raise good cholesterol, called dalcetrapib, “could be a game changer in how we treat lipid diseases,” noting it is being tested in 15,000 patients in partnership with Japan Tobacco Incmore

RECOMMENDED

Presentation skills – Your employees need training on more effective presenting. Impactiviti’s vendor/partners have just what you need.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Being purpose-full. Can you state your purpose in one minute or less to that person in the mirror?

JUST FOR FUN

25+ Amazing Cappuccino Artworks. Amazing is the right term here – wow! How could you bring yourself to drink one of these??

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS

Forbes: Pfizer‘s history of buying pipeline lemons. This does only tell one side of the story, however – Pfizer has also acquired some pretty major hits.

Speaking of flops, a couple of major experimental drugs aren’t looking so hot these days.

FDA taking another look at some bone drugs, in relation to hip fractures – There have long been safety questions — and lawsuits — over whether bone-building drugs like Merck’s Fosamax can actually increase the chance of femur fractures. Today, the FDA said it was going to take another look at the safety issuesmore

Did J&J plan to break the rules with Risperdal? Business Week reports. Plus, Shire gets a “fourfecta” warning letter from the FDA on one marketing promotion.

RECOMMENDED

Meetings/Events/Launches – Looking for creative and successful providers who can help make your off-site events a hit? We’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Nine Simple Steps to Getting Started in Social Media. Good stuff from Dose of Digital blog. For a practical guide on how YOU (as an individual) can put social networking to use building your own Opportunity Network, download my free e-book on that subject.

JUST FOR FUN

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

***

Read Full Post »

*****

TODAY’S NEWS

New experimental RA/Lupus drug suspended after patient deaths – Swiss drugmaker Roche Holding AG and U.S. biotechnology company Biogen Idec are suspending rheumatoid arthritis and lupus treatment ocrelizumab after it caused deaths, casting doubt over the drug’s futuremore

So, what about Amylin‘s Byetta? The pundits are dueling as potential once-a-week version approval draws near…

An interesting background story on Pfizer‘s expensive oncology “miracle” drug Sutent.

RECOMMENDED

Training new (or experienced) brand managers? – We’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

A “trifecta” social media approach – Novartis sponsors a community, Twitter account, and Facebook Fan Page for Cystic Fibrosis patients. How are they doing? An Impactiviti review.

JUST FOR FUN

Top 10 Most Stupid Inventions. No disagreement here!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

***

Read Full Post »

TODAY’S NEWS

Big news on the leukemia front: NovartisTasigna gets priority FDA review for newly-diagnosed patients; and Roche/Genentech‘s Rituxan approved for CLL.

A quarter of new prescriptions go unfilled.

Statins: cardiovascular benefits far outweigh the diabetes risks – Statin drugs raise the risk of diabetes significantly, but the danger appeared puny compared with their cardiovascular benefits, researchers found in a meta-analysismore

Gilead looking to ride a Quad to victory in HIV – Gilead Sciences has gone some way to ensuring that its dominance of the HIV market continues after phase II data from its “Quad” pill presented at the Conference on Retroviruses and Opportunistic Infections showed non-inferiority to its second best-selling drug, Atriplamore

Pharma eMarketing round-up: some great links and a big, thought-provoking question.

RECOMMENDED

Product launch training – If you’ve got new product launches in the plans, we have top vendor/providers to help with therapeutic area training, product modules, animations, meetings and events – just let us know. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Even Me-Too Drugs get the blues

JUST FOR FUN

I don’t recommend you try this at home! But what happens when an iMac meets a house fire? The result is…surprising, to say the least!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

Delay on inhaled insulin – a case of FDA “ooops”??

Roches‘s Actemra (RA treatment) approved by FDA – The Food and Drug Administration cleared the medicine, Actemra, in adults with moderate to severe rheumatoid arthritis, the Swiss drugmaker said today in a statement released by its South San Francisco, California-based Genentech unit. The FDA delayed approval in 2008 after the drug was backed by the agency’s outside advisersmore

All that hubbub from the story about how well anti-depressants really work: this is a pretty telling paragraph from the NY Times – That story begins to take shape when you consider what the new study actually said: Antidepressants do work for very severely depressed people, as well as for those whose mild depression is chronic. However, the researchers found, the pills don’t work for people who aren’t really depressed — people with short-term, minor depression whose problems tend to get better on their own. For many of them, it’s often been observed, merely participating in a drug trial (with its accompanying conversation, education and emphasis on self-care) can be anti-depressant enoughmore

RECOMMENDED

Curriculum Design. When it’s time to bring in some outside resources for designing curriculum (new hire, leadership, management development, etc.) we’ve got the suppliers you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Want to try a visually simple, on-line to-do list? Check out TeuxDeux.

JUST FOR FUN

A classic: The Saturday Night Live “Chicken of the Sea” skit.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

So…is Roche‘s Tamiflu really that effective? – The effectiveness of Roche Holding AG’s Tamiflu in treating flu complications in healthy adults can’t be determined because the Swiss drugmaker wouldn’t supply data from eight studies, an independent research group saidmore

The pharma layoff toll in 2009. Ugly.

Pfizer to move into biosimilars? Not a bad long-term strategy, actually: focused diversification – Pfizer Inc., which became the biggest drugmaker selling widely prescribed pills such as the Lipitor heart medicine, is preparing to enter the business of making cheaper copies of pricey, injectable drugs from biotechnologymore

Do those anti-depressants work? Maybe at a deeper level than previously thought – Antidepressant medications taken by roughly 7% of American adults cause profound personality changes in many patients with depression, far beyond simply lifting the veil of sadness, a study has found. Researchers saw strong drops in neuroticism and increases in extroversion in patients taking antidepressants, two of five traits thought to define personality and shape a person’s day-to-day thoughts and behavior. The findings are striking, researchers said, because psychologists have long thought that such fundamental traits are moorings of an adult’s personality that shift very little over a lifetimemore

RECOMMENDED

Train-the-Trainer. Looking for a well-structured but customizable program for training your new sales trainers? The Impactiviti network can help you.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Major surgery at Sanofi. How the transformation of a top 5 pharma company is taking place.

JUST FOR FUN

Not all subways are boring. Check out the architecture of these!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

 

TODAY’S NEWS

Roche: Our upcoming diabetes drug works better than Byetta. Will be interesting to see the full set of data.

AstraZeneca’s experimental oncology drug Zactima: let’s step back for a time-out.

Genta: time to give up on Genasense? Not sure this horse is ever going to gallop.

RECOMMENDED

Compliance Training. Impactiviti’s partner network includes solutions providers for every level of compliance training – from sales reps to home office employees. Ethics, Regulatory compliance, Diversity – you name it. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

This week, I attended a very enjoyable ePatient Connection conference (put on by Kevin Kruse). It was excellent: here’s a review.

JUST FOR FUN

Curious about all that wine flavor jargon? Check out this neat little visualization!
—–——–
Coming up next week:

eComm

Nov. 3-4 – eyeforpharma’s 4th Annual eCommunication and On-line Marketing Summit, Philadelphia, PA. I’ll be part of a panel on social networking, and live-blogging/Twittering. Here’s a discount code to save $400 off your registration: SPEAK

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Tune in TODAY – I’ll be doing a live on-line interview on Social Media in Pharma with Paul Chaney – starts at 1 pm EST (just use the call-in number – see the link). Also, here’s a page on my site with all sorts of social media resources for pharma professionals: http://bit.ly/socialrx

TODAY’S NEWS

AstraZeneca’s new Plavix-competitor Brilinta expected to go big – It is the first antiplatelet drug to demonstrate it can reduce cardiovascular (CV) deaths compared to the current gold standard treatment, Plavix (clopidogrel) in patients with acute coronary syndromes (ACS). Results of the 18600 patient Phase III PLATO trial comparing the two drugs, were revealed at the recent European Society of Cardiology (ESC) Congress in Barcelona…Platelet expert Dr Victor Serebruany agreed the mortality data is ”marvelous,” with 107 extra lives saved compared to Plavix. “It has never been seen before and no one expected it,” he saidmore

Big oncology news (approval for new lymphoma drug) today – Allos Therapeutics Inc. said Friday that regulators approved its injectable drug Folotyn as a treatment for peripheral T-cell lymphoma, a group of rare, agressive blood cancers, sending its shares soaring. Allos said the Food and Drug Administration granted accelerated approval, allowing the company to market Folotyn for use in patients whose cancer has returned or not responded to previous treatment. Allos expects to begin selling the drug in October. There are no drugs on the market that treat peripheral T-cell lymphoma, Allos saidmore Plus, some future hope from Roche on melanoma?

So the FDA is finally going to start wresting with social media in pharma! Here’s what companies need to do to prepare for the hearing this fall. And here also.

This bothers me.

RECOMMENDED

Compliance training. When y0u need compliance training development partners for your employees, we’ve got g. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

An interview with the President and CEO of Sanofi-Aventis US (Gregory Irace), on the big changes they are undergoing to re-structure the company, and the way they deliver information.

Coming up next month:

DigitalPharma

Oct. 19-21 – eXL’s Digital Pharma conference, Bridgewater, NJ. This event will be quite progressive, with more of an informal “unconference” format to maximize interaction. I’ll be co-leading a pre-conference workshop on the 19th on social media, and live-blogging/Twittering. Here’s a discount code for 15% your registration: P615WOO

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

Osteoporosis. The status of new treatments from Wyeth, Pfizer, and Amgen.

FDA approves H1N1 vaccines – The Food and Drug Administration on Tuesday approved vaccines designed to protect against the H1N1 influenza virus, a key step before starting a vaccination campaign. The approval was announced by Health and Human Services Secretary Kathleen Sebelius at a hearing that was held by the House Energy and Commerce Committee. An FDA spokeswoman said the agency approved vaccines made by a unit of Sanofi-Aventis SA, Novartis AG, CSL Ltd. and AstraZeneca PLC’s MedImmune unitmore

Roche‘s anemia drug Mircera – not coming to a pharmacy near you.

Pfizer math.”

Interesting. Less than 1% of doctors see bias in on-line CME? What do you think?

Social Media Monitoring – should pharma bother? Only if you plan to act on it…

RECOMMENDED

Gaming and Simulations. Training and marketing don’t have to be boring. The Impactiviti Partner network has great technology vendor/partners who develop games and simulations. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

Ben & Jerry’s. I visited their HQ in Vermont for a tour last week – a very impressive marketing approach. Here are my impressions.

JUST FOR FUN

Not just for wussy little boys. Less than a minute will get you a good chuckle!

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

Older Posts »